Phase I clinical study of a combined modality treatment of sarcomas of the extremities or in head and neck area with radiotherapy (RT) and dose-escalation of Pazopanib
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PASART-1
- 03 Feb 2025 New trial record
- 15 Jan 2025 Results (n=34) assessing long-term follow-up data from PASART-1 and PASART-2 studies and comparing these data during the same time period with the Netherlands Cancer Registry (IKNL), published in the Acta Oncologica.